Angiogenesis regulation system

Details Angiogenesis regulation system Angiogenesis regulation system

2004-12-23

2008-12-09

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C530S300000

Reexamination Certificate

active

07462355

ABSTRACT:
Stable water soluble polypeptides which are potent inhibitors of endothelial cell proliferation and of angiogenesis. Polypeptide inhibitors of endothelial cell growth may have important uses in the elucidation of the mechanism of angiogenesis, disease diagnosis and prognostication, and drug therapies for use in animals and humans.

REFERENCES:
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 6200954 (2001-03-01), Ge et al.
patent: 6201104 (2001-03-01), MacDonald et al.
patent: 6346510 (2002-02-01), O'Reilly et al.
patent: WO9110424 (1991-07-01), None
patent: WO9316716 (1993-09-01), None
patent: WO9525543 (1995-09-01), None
patent: WO9529242 (1995-11-01), None
Dooley CT et al. “Acetalins: opioid receptor antagonists determined through the use of synthetic peptide combinatorial libraries”. Proc Natl Acad Sci U S A. Nov. 15, 1993;90(22):10811-5.
“Dual Drug Treatment eradicates cancer in mice”, CNN, http://cnn.com/HEALTH/9805/03/cancer.mice, May 3, 1998, pp. 1-3.
“Methods for Treating Tumors Using Anti-Angiogenic Compounds”, Steven K. Libutti et al, http://www.nih.gov/od/ott/0-133243.html, May 7, 1999, p. 1.
“Fighting Cancer with Angiogenesis Inhibitors”, Angiogenesis Inhibitors, /www.ultranet.com/˜jkimball/BiologyPages/A/Angiogenesis.html, Mar. 31, 2000, pp. 1-2.
“Angiostatin and Endostatin Scientific Abstracts”, http://www.lef.org/protocols/abstracts/cancertreat-abstr.html, Mar. 31, 2000, pp. 1-7.
“Endostatin reduces atherosclerosis in mice”, http://www/biomed.lib.umn.edu/hmed/99046—end.html, Mar. 31, 2000, p. 1.
“Endostatin reduced plaque development in mice”, Cardiology Today, /www.slackinc.com/general/carcio/199908/mouse.asp, Aug. 1999, pp. 1-3.
“Sign-Ups begin for Trials of Tumor-Shrinking Cancer Drug”, The Boston Globe, http://www.slip.net/˜mcdavis/database/endost—5.htm, Sep. 30, 1999, pp. 1-2.
“Harvard Cancer Research Questioned”, The Associated Press, http://www.slip.net/˜mcdavis/database/angio188.htm, Nov. 13, 1998, pp. 1-2.
“Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance”, Nature, /www.slip.net/˜mcdavis/dbas9697/98049348.htm, 390(6658):404-7 1997.
“Future Anti-Angiogenic Therapy with Endostatin”, Patricia Reaney, http://www.slip.net/˜mcdavis/database/angio43.htm, Nov. 26, 1997, pp. 1-2.
“Drug Starves Tumors”, Leslie Papp, http://www.slip.net/˜mcdavis/database/endost—2.htm, Mar. 31, 2000, pp. 1-2.
“EntreMed Inc. announces Publication of Positive Preclinical Findings Using Endostatin™ Protein Therapy in Experimental Cancer”, Business Wire, www.slip.net/˜mcdavis/database/endost/—3.htm, Dec. 1, 1997, pp. 1-2.
Standker, L. et al., FEBS letters 420, 1997, pp. 129-133.
Algire, G.H. et al., “Vascular reactions of normal and malignant tumors in vivo. 1. Vascular reactions of mice to wounds and to normal and aneoplastic transplants”, J. Natl. Canc. Inst., vol. 6, pp. 73-85 (1945).
Chen, C. et al., “A Strategy to Discover Circulating Angiogenesis Inhibitors Generated by Human Tumors”, Canc Resch., vol. 55, pp. 4230-4233 (1995).
Grant, D.S. et al., “Scatter factor induces blood vessel formation in vivo”, Proc. Natl. Acad. Sci. USA, vol. 99, pp. 1937-1941 (1993).
Muragaki, Y. et al., “Mouse col. 18al is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones”, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 8763-8767 (1995).
Studier, W.F. et al., “Use of T7 RNA polymerase to direct expression of cloned genes”, Methods Enzymol., vol. 185, pp. 60-89 (1990).
Abe et al. Blochem. Biophs Res Comm. 196:576-582, Oct. 1993.
Oh et al. ProC. Natl. Acad. Sci. USA 91:4229-33, May 1994.
Rehn et al. J. Biol. Chem. 269: 13929-35, May 13, 1994.
Drug News 3:482 May 9, 1997, 1990.
Abe, N. et al., “Identification of a Novel Collagen Chain Represented by Extensive Interruptions in the Triple-Helical Region”, Blochem. and Biophys. Resch. Comm., vol. 196, No. 2, pp. 576-582 (1993).
Angiolillo, A.I. et al., “Human interferon-inducible Protein 10 is a potent inhibitor of angiogenesis in vivo”, J. Exp. Med., vol. 182, pp. 155-162 (1995).
Brem, H. et al., “Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas”, J. Neurosurg., vol. 74, pp. 441-446 (1991).
Brockway, W.J. et al., “Measurement of the Binding of Antifibrinolytic Amino Acids to Various Plasminogens”, Arch. Blochem. Blophys., vol. 15 1, pp. 194-199 (1972).
Browne, M.J. et al., “Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells”, Fibrinolysis, vol. 5, pp. 257-260 (1991).
Cao, Y. et al., “gro-.beta., alpha. -C-X-C-Chemokine, Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice”, J. Exp. Med., vol. 182, pp. 2069-2077 (1995).
Clapp, C. et al., “The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis”, Endocrinology, vol. 133, pp. 1292-1299 (1993).
Cleary, S. Mulkerrin et al., “Purification and Characterization of Tissue Plasminogen Activator Kringle.sup.2 Domain Expressed inEscherichia coli”, Biochem., vol. 28, pp. 1884-1891 (1989).
Dameron, K.M. et al., “Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1”, Science, vol. 265, pp. 1585-1584 (1994).
Folkman, J., “Tumor angiogenesis and tissue factor”, Nature Med. vol. 2, pp. 167-168.
Folkman, J., “What is the Evidence that Tumors are Angiogenesis Dependent?”, J. Natl Cane Inst., vol. 82, pp. 4-6 (1990).
Folkman, J., “Angiogenesis in cancer, vascular, rheumatoid and other disease”, Nature Medicine, vol. 1, No. 1, pp. 27-31 (1995).
Folkman, J., “Long-term culture of capillary endothelial cells”, Proc. Natl. Acad. Sci. USA 76, pp. 5217-5221 (1979).
Folkman, J., et al., “Induction of angiogenisis during the transition form hyperplasia to neoplasia”, Nature, vol. 339, pp. 58-61 (1989).
Folkman, J. et al., “Tumor Behavior in Isolated Perfused Organs In Vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment”, Annals of Surgery, vol. 164, No. 3, pp. 491-501 (1996).
Folknian, J., “Angiogenesis and Its Inhibitors”, Important Advances in Oncology, J.B. Lippincott Company, pp. 42-62 (1985).
Folkman, J., “Tumor Angiogenesis Therapeutic Implications”, NE J. of Med., No. 18, pp. 1182-1186 (1971).
Gavriell, Y. et al., “Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation”, J. CellBiol., vol. 119, pp. 493-501 (1992).
Gimbrone, M.A. et al., “Tumor Growth and Neovasculanization An Experimental Model using the Rabbit Cornea”, J. Natl. Canc. Inst., vol. 52, No. 2 pp. 413-427 (1974).
Gimbrone, M.A. et al., “Tumor Dormancy in Vivo by Prevention of Neovascularization”, J. of Experi. Med., vol. 136, pp. 261-276 (1972).
Good, D.J. et al., “A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin”, Proc. Nat. Acad. Sci. USA, vol. 87, pp. 6624-6628 (1990).
Grant, D.S. et al., “Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro”, Cell, vol. 58, pp. 933-943 (1989).
Gross, J.L. et al., “Modulation of Solid Tumor Growth in vivo by bFGF”, Proc. Amer. Assoc. Canc. Resh, vol. 3 1, p. 79 (1990).
Gross, J.L. et al., “Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro.”, Proc. Natl. Acad. Sci. USA, vol. 80, pp. 2623-2627 (1983).
Gunzler, W.A. et

Affiliated with

Also associated with

Rating

Angiogenesis regulation system does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Angiogenesis regulation system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenesis regulation system will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4025700